RepliCel Life Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Schutte
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 570 Granville Street Vancouver BC Canada V6C 3P1
- IPO Date
- May 3, 2010
- CIK
- 0001205059
- Website
- replicel.com
- Similar Companies
- Business
- RepliCel Life Sciences Inc. (OTCPK: REPCF) develops autologous cell therapies and related medical devices for regenerative medicine applications in aesthetics and orthopedics, focusing on conditions caused by deficits of healthy cells such as aging or sun-damaged skin, pattern baldness, and chronic tendon degeneration; its core products include RCH-01 cell therapy for androgenetic alopecia hair restoration, RCS-01 cell therapy for skin rejuvenation, RCT-01 cell therapy for tendon repair in areas like the ankle, knee, elbow, and shoulder, and DermaPrecise, a next-generation programmable dermal injection device with consumables to enhance administration of injectables. Founded in 2011 and headquartered in Vancouver, British Columbia, Canada, the company sources proprietary cell populations from patients' hair follicles via non-invasive biopsies and holds rights to these therapies outside Greater China, where exclusive licenses for RCT-01, RCS-01, and DermaPrecise in dermatology applications are held by YOFOTO (China) Health Industry Co. Ltd., with MainPointe Pharmaceuticals holding exclusive U.S. distribution rights for DermaPrecise subject to milestones. In August 2024, RepliCel entered definitive agreements to license its patent rights and sell related assets, know-how, branding, and hardware for its cell therapies and DermaPrecise to 1456390 B.C. Ltd. (NumberCo), a related entity controlled by CEO Andrew Schutte, in exchange for an 8% royalty on gross profits up to US$2.00 per fully diluted share plus 75% of any third-party sale proceeds; the transaction closed in February 2025, enabling RepliCel to pursue voluntary delisting from the TSX Venture Exchange, revoke U.S. Securities Exchange Act registration, and distribute royalties as dividends after expenses, while NumberCo advances commercialization.
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
RepliCel Adds Independent Director
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
RepliCel Announces Record Year in Patents Granted
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
RepliCel Closes Second Tranche of Strategic Investment Commitment
RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership